Conivaptan
![Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set](http://data.docslib.org/img/264x/135084d885a0ce0d8ef8f9f83426c79a.webp)
Top View
- Pharmacokinetics of Conivaptan Use in Patients with Severe Hepatic Impairment
- Fluids and Diuretics
- Anatomical Classification Guidelines V2018 EPHMRA ANATOMICAL
- Download Download
- Drugs Involved in Significant Pharmacokinetic Drug-Drug Interactions in 2015
- Vaptans and Hyponatremia in Critical Patients
- Examples of Prohibited and Permitted Substances And
- Samsca, INN-Tolvaptan
- Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-Cov-2
- Rational Management of Hospitalized Patients with Hyponatremia: Application to Patient Cases
- ATC-Index Mit DDD-Angaben Für Den Deutschen Arzneimittelmarkt Berlin 2013, 12
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- The Treatment of Vasopressin V2-Receptor Antagonists in Cirrhosis Patients with Ascites
- VAPRISOL® (Conivaptan Hydrochloride Injection)
- Emerging Drug Therapies for Heart Failure
- The Role of V2 Receptor Antagonists in the Treatment of Hyponatremia
- 7-Renal Drugs FINAL
- Clinical Use of Diuretics in Heart Failure, Cirrhosis, and Nephrotic Syndrome